What does DuoGenic StemCells corporation do?

DuoGenic StemCells corporation (7607.TWO) operates in the Medical - Specialties industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.

What is 7607.TWO's market cap?

DuoGenic StemCells corporation (7607.TWO) has a market capitalization of approximately $436.2 million, as of August 27, 2026, based on the most recent share price and shares outstanding.

Does 7607.TWO pay a dividend?

No — DuoGenic StemCells corporation (7607.TWO) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.

Is 7607.TWO profitable?

DuoGenic StemCells corporation (7607.TWO) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.

7607.TWO

DuoGenic StemCells corporation

TWO·Medical, Specialties · Healthcare

NT$11.90NT$0.35−2.86%

Market capNT$436.17M·Market closed·Aug 27 5:23 AM UTC

Price Chart

NT$11.90−NT$0.35 (−2.86%)today

−81.11%CAGR −40.04%

Select date range

FromTo

May 25, 2023May 25, 2023 → Aug 27, 2026· 3.3 yrsAug 27, 2026

Key Metrics

7607.TWO does not currently pay a dividend.

EarningsEarnings Tab

EPS (FWD)—

P/E Ratio (FWD)—

EPS Growth (1Y)—

EPS Growth (3Y)—

EPS Growth (5Y)—

Next Earnings Date—

Last Report Date—

Reported vs Estimate—

Earnings Surprise—

FinancialsFinancials Tab

RevenueNT$20.60M

Net Income−NT$34.33M

Net Margin−166.7%

Operating Cash Flow−NT$41.48M

Capital ExpendituresNT$2.06M

Free Cash Flow−NT$43.53M

Return on Equity−82.1%

Return on Invested Capital−32.4%

Net CashNT$6.06M

Value Graph

PRO

See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.

Click below to see what's inside, then upgrade to unlock for 7607.TWO and 80,000+ other tickers.

EPS · Price vs. Fair Value Price Fair

Income Statement Flow

PRO

See exactly how 7607.TWO's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.

The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for 7607.TWO and 80,000+ other tickers.

About DuoGenic StemCells corporation

Duogenic Stemcells Corporation is primarily engaged in the biotechnology and healthcare industries, offering a variety of services. Their core offerings include cell therapy and the development of closed-culture cell systems. The company was established on March 22, 2018, and its main corporate office is situated in Taichung, Taiwan.

CEO: Chih Yao Lin
Sector: Healthcare
Industry: Medical - Specialties
Exchange: TWO
Employees: 15
Website: www.dgsc.com.tw

Peers

Peers Tab

4183.TWO

EPS Bio Technology Corp.

Cap

NT$333.2M

6797.TWO

Taiwan Advanced Nanotech Inc.

Latest News

News Tab

No recent news available.

Frequently Asked Questions About 7607.TWO

What does DuoGenic StemCells corporation do?: DuoGenic StemCells corporation (7607.TWO) operates in the Medical - Specialties industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.
What is 7607.TWO's market cap?: DuoGenic StemCells corporation (7607.TWO) has a market capitalization of approximately $436.2 million, as of August 27, 2026, based on the most recent share price and shares outstanding.
Does 7607.TWO pay a dividend?: No — DuoGenic StemCells corporation (7607.TWO) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.
Is 7607.TWO profitable?: DuoGenic StemCells corporation (7607.TWO) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.